New Data Shows Intradermal Administration of Mycoplasma Vaccines More Efficient Than Standard Methods
Data Presented at Fifth European Symposium of Porcine Health Management in Scotland
BOXMEER, NETHERLANDS 11 JULY 2013 – MSD Animal Health (known as Merck Animal Health in the USA and Canada) hosted a symposium featuring data supporting the efficacy of intradermal administration of new mycoplasma vaccines compared to standard intramuscular vaccination in swine. The event was held prior to the start of the 5th European Symposium of Porcine Health Management in Edinburgh, Scotland on May 21 and May 22.
The double-blind, controlled study evaluated the local and systemic immune response induced by mycoplasma vaccines in swine. Vaccines were formulated to deliver the same amount of antigen content either intradermally with the IDAL vaccinator device (MSD Animal Health) or intramuscularly by standard syringe application. These treatments were compared to a control group given a placebo.
Based on Mycoplasma hyopneumoniae (M. hyopneumoniae) antibodies measured in blood and bronchoalveolar lavage (BAL), fluid samples, collected in vivo, intradermal administration appeared to stimulate the immune system at least as efficiently as the intramuscular administration, if not better. In addition, the data supported that intradermal administration engages a more efficient stimulation of the mucosal and cell mediated immunity.
M. hyopneumoniae causes significant reduction in the growing weight of pigs and treatment, once infected, is limited to antibiotics that may not be effective.
“This highly contagious chronic respiratory disease in swine can have severe economic impact for farmers,” explains Dr. Rika Jolie, Director, Scientific Marketing Affairs, MSD Animal Health. “An effective means of vaccination against this disease can help farmers with the management of herd health.”
Intradermal vaccination is an animal-friendly option, is less painful and stressful for the pigs at time of application, and has better hygiene and less potential for spread of disease. The intradermal application also provides a safer means of administering the vaccine with no implications to the quality of the meat.
About MSD Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. MSD Animal Health, known as Merck Animal Health in the United States and Canada, is the global animal health business unit of Merck. MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com.
Merck forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2012 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
IDAL™ is a registered trademark of MSD Animal Health, Summit N.J., USA